BACKGROUND: There are few prospective data on the prognosis of insulin-sensitive and insulin-resistant normal-weight (NW) or obese individuals. OBJECTIVES: The estimated liver fat content, incidences of hyperglycemia and cardiovascular disease, and all-cause and cardiovascular mortality rates were investigated in a population-based cohort of 1658 individuals who were categorized according to BMI and insulin resistance as defined by HOMA-IR values ≥2.5 and the presence of metabolic syndrome. DESIGN: This was a prospective cohort study with a 9-y follow-up. Anthropometric values, blood pressure, and blood metabolic variables were measured, and information on vital status was collected from demographic files at follow-up. RESULTS: A total of 137 of 677 NW individuals (20%) were classified as insulin resistant and normal weight (IR-NW), and 72 of 330 obese individuals (22%) were classified as insulin sensitive and obese (IS-obese). Incidences of diabetes, impaired fasting glucose, and cardiovascular events were 0.4%, 6.3%, and 3.3%, respectively, in insulin-sensitive and normal-weight (IS-NW) individuals (reference category); 5.8%, 10.2%, and 6.6%, respectively, in IR-NW individuals; and 5.6%, 8.3%, and 8.3%, respectively, in IS-obese individuals. In a multiple logistic regression model, risks of incident hyperglycemia and cardiovascular events increased in both groups compared with in the reference category [HR (95% CI): 2.54 (1.42, 4.55) and 1.98 (0.86, 4.54) in IR-NW subjects; 2.16 (1.01, 4.63) and 2.76 (1.05, 7.28) in IS-obese subjects]. The estimated liver fat content significantly increased during follow-up only in the IR-NW group in the same model. Cardiovascular mortality was 2-3-fold higher in IR-NW and IS-obese than in IS-NW individuals in a Cox regression model. CONCLUSIONS: Our data refute the existence of healthy obese phenotypes because IS-obese individuals showed increased cardiometabolic risk. The existence of unhealthy NW phenotypes is supported by their increased risk of incident hyperglycemia, fatty liver, cardiovascular events, and death.
BACKGROUND: There are few prospective data on the prognosis of insulin-sensitive and insulin-resistant normal-weight (NW) or obese individuals. OBJECTIVES: The estimated liver fat content, incidences of hyperglycemia and cardiovascular disease, and all-cause and cardiovascular mortality rates were investigated in a population-based cohort of 1658 individuals who were categorized according to BMI and insulin resistance as defined by HOMA-IR values ≥2.5 and the presence of metabolic syndrome. DESIGN: This was a prospective cohort study with a 9-y follow-up. Anthropometric values, blood pressure, and blood metabolic variables were measured, and information on vital status was collected from demographic files at follow-up. RESULTS: A total of 137 of 677 NW individuals (20%) were classified as insulin resistant and normal weight (IR-NW), and 72 of 330 obese individuals (22%) were classified as insulin sensitive and obese (IS-obese). Incidences of diabetes, impaired fasting glucose, and cardiovascular events were 0.4%, 6.3%, and 3.3%, respectively, in insulin-sensitive and normal-weight (IS-NW) individuals (reference category); 5.8%, 10.2%, and 6.6%, respectively, in IR-NW individuals; and 5.6%, 8.3%, and 8.3%, respectively, in IS-obese individuals. In a multiple logistic regression model, risks of incident hyperglycemia and cardiovascular events increased in both groups compared with in the reference category [HR (95% CI): 2.54 (1.42, 4.55) and 1.98 (0.86, 4.54) in IR-NW subjects; 2.16 (1.01, 4.63) and 2.76 (1.05, 7.28) in IS-obese subjects]. The estimated liver fat content significantly increased during follow-up only in the IR-NW group in the same model. Cardiovascular mortality was 2-3-fold higher in IR-NW and IS-obese than in IS-NW individuals in a Cox regression model. CONCLUSIONS: Our data refute the existence of healthy obese phenotypes because IS-obese individuals showed increased cardiometabolic risk. The existence of unhealthy NW phenotypes is supported by their increased risk of incident hyperglycemia, fatty liver, cardiovascular events, and death.
Authors: Shuo Wang; Mark D Lo Galbo; Cindy Blair; Bharat Thyagarajan; Kristin E Anderson; DeAnn Lazovich; Anna Prizment Journal: Maturitas Date: 2020-08-11 Impact factor: 4.342
Authors: Lara L Roberson; Ehimen C Aneni; Wasim Maziak; Arthur Agatston; Theodore Feldman; Maribeth Rouseff; Thinh Tran; Michael J Blaha; Raul D Santos; Andrei Sposito; Mouaz H Al-Mallah; Ron Blankstein; Matthew J Budoff; Khurram Nasir Journal: BMC Public Health Date: 2014-01-08 Impact factor: 3.295
Authors: Luca A Lotta; Ali Abbasi; Stephen J Sharp; Anna-Stina Sahlqvist; Dawn Waterworth; Julia M Brosnan; Robert A Scott; Claudia Langenberg; Nicholas J Wareham Journal: Diabetes Care Date: 2015-11 Impact factor: 19.112
Authors: Dana Dabelea; Jennifer W Talton; Ralph D'Agostino; R Paul Wadwa; Elaine M Urbina; Lawrence M Dolan; Stephen R Daniels; Santica M Marcovina; Richard F Hamman Journal: Diabetes Care Date: 2013-10-07 Impact factor: 19.112
Authors: Neil Murphy; Amanda J Cross; Mustapha Abubakar; Mazda Jenab; Krasimira Aleksandrova; Marie-Christine Boutron-Ruault; Laure Dossus; Antoine Racine; Tilman Kühn; Verena A Katzke; Anne Tjønneland; Kristina E N Petersen; Kim Overvad; J Ramón Quirós; Paula Jakszyn; Esther Molina-Montes; Miren Dorronsoro; José-María Huerta; Aurelio Barricarte; Kay-Tee Khaw; Nick Wareham; Ruth C Travis; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Giovanna Masala; Vittorio Krogh; Rosario Tumino; Paolo Vineis; Salvatore Panico; H Bas Bueno-de-Mesquita; Peter D Siersema; Petra H Peeters; Bodil Ohlsson; Ulrika Ericson; Richard Palmqvist; Hanna Nyström; Elisabete Weiderpass; Guri Skeie; Heinz Freisling; So Yeon Kong; Kostas Tsilidis; David C Muller; Elio Riboli; Marc J Gunter Journal: PLoS Med Date: 2016-04-05 Impact factor: 11.069